D. Western Therapeutics Institute (FRA:6DW) EBIT: €-1.90 Mil (TTM As of Dec. 2025)


FRA:6DW D. Western Therapeutics Institute Inc FRA:6DW
22 GF Score
Price €0.39
GF Value €0.31
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is D. Western Therapeutics Institute EBIT?

D. Western Therapeutics Institute FRA:6DW -1.03% 22 EBIT is €-1.90 Mil as of Dec. 2025. GuruFocus rates FRA:6DW with a GF Score™ of 22/100 and a GF Value™ of €0.31 (Modestly Overvalued). The stock has 3 warning signs investors should review.

D. Western Therapeutics Institute's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was €0.00 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.90 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. D. Western Therapeutics Institute's annualized ROC % for the quarter that ended in Dec. 2025 was 0.00%. D. Western Therapeutics Institute's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 0.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. D. Western Therapeutics Institute's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -9.33%.


D. Western Therapeutics Institute  (FRA:6DW) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

D. Western Therapeutics Institute's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=0 * ( 1 - 0% )/( (2.342 + 2.151)/ 2 )
=0/2.2465
=0.00 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

D. Western Therapeutics Institute's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0/( ( (0.067 + max(1.237, 0)) + (0.051 + max(1.126, 0)) )/ 2 )
=0/( ( 1.304 + 1.177 )/ 2 )
=0/1.2405
=0.00 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.484 + 0.597 + 0.678) - (0.452 + 0 + 0.07)
=1.237

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.518 + 0.476 + 0.706) - (0.367 + 0 + 0.207)
=1.126

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

D. Western Therapeutics Institute's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-1.896/20.319
=-9.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


D. Western Therapeutics Institute EBIT Related Terms


D. Western Therapeutics Institute EBIT Historical Data

* Premium members only.

The historical data trend for D. Western Therapeutics Institute's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

D. Western Therapeutics Institute EBIT Chart

D. Western Therapeutics Institute Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.21 -3.06 -5.25 -7.97 -3.41

D. Western Therapeutics Institute Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.92 -0.99 0.00 -0.91

FRA:6DW vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, D. Western Therapeutics Institute's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


D. Western Therapeutics Institute EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, D. Western Therapeutics Institute's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where D. Western Therapeutics Institute's EV-to-EBIT falls into.


FRA:6DW
22GF Score
D. Western Therapeutics Institute Inc FRA:6DW
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

D. Western Therapeutics Institute EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-1.90 Mil mean?
D. Western Therapeutics Institute (FRA:6DW) has a EBIT of €-1.90 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on D. Western Therapeutics Institute.
Is D. Western Therapeutics Institute's EBIT too high?
D. Western Therapeutics Institute's current EBIT is €-1.90 Mil. Overall, D. Western Therapeutics Institute has a GF Score™ of 22/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does D. Western Therapeutics Institute's EBIT compare to VRTX and REGN?
D. Western Therapeutics Institute's EBIT of €-1.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on D. Western Therapeutics Institute. D. Western Therapeutics Institute's current EBIT is €-1.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is D. Western Therapeutics Institute stock overvalued right now?
Based on GuruFocus' analysis, D. Western Therapeutics Institute (FRA:6DW) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.31, compared to a current price of €0.39 — trading 24.5% above its estimated fair value. The current EBIT is €-1.90 Mil. D. Western Therapeutics Institute's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For D. Western Therapeutics Institute (FRA:6DW), the current EBIT is €-1.90 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is D. Western Therapeutics Institute (FRA:6DW) Overvalued in 2026?

Based on GuruFocus' analysis, D. Western Therapeutics Institute stock appears to be overvalued. The current stock price of €0.39 is trading 24.5% above its estimated GF Value™ of €0.31. GuruFocus considers D. Western Therapeutics Institute to be Modestly Overvalued.

Key valuation signals for FRA:6DW:

  • EBIT: €-1.90 Mil
  • GF Value™: €0.31 vs. price of €0.39 (24.5% above fair value)
  • GF Score™: 22/100 with 3 warning signs

No single metric tells the full story. See the FRA:6DW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


D. Western Therapeutics Institute Business Description

Other Exchanges 4576:Japan
Address 7th Floor, 18 KT Bulding, 1-18-11, Nishiki, Naka-ku, Aichi, Nagoyashi, JPN, 460-0003
D. Western Therapeutics Institute Inc is engaged in the research and development of pharmaceutical drugs in Japan. Its products include ophthalmic solution and agents for antiplatelet and anti-glaucoma.
22GF Score

Get the complete analysis for FRA:6DW

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.39
Price
€0.31
GF Value